How to get ARESTINbreadcrumb separatorARESTIN Rx Access Portal

The ARESTIN Rx Access Portal

The ARESTIN Rx Access Portal allows you to submit your prescriptions online and conveniently track the status of all of your submitted prescriptions online,* by phone, or by fax.

Login / Register

Watch this video for a quick tour of the ARESTIN Rx Access Portal.

ARESTIN Rx Access Portal tips

Here are some important things to know about working with the ARESTIN Rx Access Portal. You can also download a Portal Tips Guide to learn simple navigation tools.

Tip #1

Turn off pop-up blockers to allow prescriptions to be printed

To print a prescription submission you must turn off your browser’s pop-up blocker. After clicking the “Submit and Print” button, the prescription will automatically be sent to the ARESTIN Rx Access Coordinator for processing. A paper copy can only be printed if the pop-up blocker is turned off.

Tip #2

Refresh the page for “real-time” status

Click the “Refresh” circular arrow button in the top right corner of the tracker window every time you check the status of a prescription. Refreshing the prescription tracker will help determine if an online prescription submission was successfully entered into the system and ensure that you are seeing the most up-to-date information.

Tip #3

Sign all prescriptions to enable tracking

Prescriptions submitted by both express and standard service, as well as online,* will be visible in the tracker. To complete the submission, please provide the doctor’s final signature on the prescription form and fax it back to the ARESTIN Rx Access Coordinator. A benefit summary will be sent to you via fax within 24 hours of a complete submission.

If coverage is denied

Similar to dental benefits, ARESTIN coverage is determined by a patient's plan. Don't be discouraged by occasional denials; every patient carries different coverage so it pays to be persistent. Evaluate your approval rate after the submission of at least 10 prescriptions to establish a baseline.

Contact the ARESTIN Rx Access Service Center at 1-855-684-7481 if you have any questions.

*Login required. Visit RxAccessPortal.com to create an account for the ARESTIN Rx Access Online Portal.

INDICATION

ARESTIN® (minocycline HCl) Microspheres, 1mg is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN® may be used as part of a periodontal maintenance program, which includes good oral hygiene and SRP.

IMPORTANT SAFETY INFORMATION

  • ARESTIN is contraindicated in any patient who has a known sensitivity to minocycline or tetracyclines. Hypersensitivity reactions and hypersensitivity syndrome that included, but were not limited to anaphylaxis, anaphylactoid reaction, angioneurotic edema, urticaria, rash, eosinophilia, and one or more of the following: hepatitis, pneumonitis, nephritis, myocarditis, and pericarditis may be present. Swelling of the face, pruritus, fever and lymphadenopathy have been reported with the use of ARESTIN. Some of these reactions were serious. Post-marketing cases of anaphylaxis and serious skin reactions such as Stevens Johnson syndrome and erythema multiforme have been reported with oral minocycline, as well as acute photosensitivity reactions.
  • THE USE OF DRUGS OF THE TETRACYCLINE CLASS DURING TOOTH DEVELOPMENT MAY CAUSE PERMANENT DISCOLORATION OF THE TEETH, AND THEREFORE SHOULD NOT BE USED IN CHILDREN OR IN PREGNANT OR NURSING WOMEN.
  • Tetracyclines, including oral minocycline, have been associated with development of autoimmune syndromes including a lupus-like syndrome manifested by arthralgia, myalgia, rash, and swelling. Sporadic cases of serum sickness-like reaction have presented shortly after oral minocycline use, manifested by fever, rash, arthralgia, lymphadenopathy and malaise. In symptomatic patients, diagnostic tests should be performed and ARESTIN treatment discontinued.
  • The use of ARESTIN in an acutely abscessed periodontal pocket or for use in the regeneration of alveolar bone has not been studied.
  • The safety and effectiveness of ARESTIN has not been established in immunocompromised patients or in those with coexistent oral candidiasis. Use with caution if there is a predisposition to oral candidiasis.
  • In clinical trials, the most frequently reported nondental treatment-emergent adverse events were headache, infection, flu syndrome, and pain.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch Health US, LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Click here for full Prescribing Information.

This site is published by OraPharma, a division of Bausch Health Companies Inc., which is solely responsible for its contents. It is intended for visitors from the United States.

OraPharma Logo®/TM are trademarks of Bausch Health Companies Inc. or its affiliates.
©2020 Bausch Health Companies Inc. or its affiliates.   ARE.0232.USA.20


CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION

INDICATION

ARESTIN® (minocycline HCl) Microspheres, 1mg is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN® may be used as part of a periodontal maintenance program, which includes good oral hygiene and SRP.

IMPORTANT SAFETY INFORMATION

  • ARESTIN is contraindicated in any patient who has a known sensitivity to minocycline or tetracyclines. Hypersensitivity reactions and hypersensitivity syndrome that included, but were not limited to anaphylaxis, anaphylactoid reaction, angioneurotic edema, urticaria, rash, eosinophilia, and one or more of the following: hepatitis, pneumonitis, nephritis, myocarditis, and pericarditis may be present. Swelling of the face, pruritus, fever and lymphadenopathy have been reported with the use of ARESTIN. Some of these reactions were serious. Post-marketing cases of anaphylaxis and serious skin reactions such as Stevens Johnson syndrome and erythema multiforme have been reported with oral minocycline, as well as acute photosensitivity reactions.
  • THE USE OF DRUGS OF THE TETRACYCLINE CLASS DURING TOOTH DEVELOPMENT MAY CAUSE PERMANENT DISCOLORATION OF THE TEETH, AND THEREFORE SHOULD NOT BE USED IN CHILDREN OR IN PREGNANT OR NURSING WOMEN.
  • Tetracyclines, including oral minocycline, have been associated with development of autoimmune syndromes including a lupus-like syndrome manifested by arthralgia, myalgia, rash, and swelling. Sporadic cases of serum sickness-like reaction have presented shortly after oral minocycline use, manifested by fever, rash, arthralgia, lymphadenopathy and malaise. In symptomatic patients, diagnostic tests should be performed and ARESTIN treatment discontinued.
  • The use of ARESTIN in an acutely abscessed periodontal pocket or for use in the regeneration of alveolar bone has not been studied.
  • The safety and effectiveness of ARESTIN has not been established in immunocompromised patients or in those with coexistent oral candidiasis. Use with caution if there is a predisposition to oral candidiasis.
  • In clinical trials, the most frequently reported nondental treatment-emergent adverse events were headache, infection, flu syndrome, and pain.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch Health US, LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Click here for full Prescribing Information.

Click here for IMPORTANT SAFETY INFORMATION